FORCE

Women with a family history of breast and ovarian cancer who are interested in getting genetically tested to gauge whether they have a heightened risk for the diseases should speak to a genetic counselor before getting tested, patient groups are advising their members.

This article has been updated to correct that Ellen Matloff is a plaintiff in AMP v. USPTO.

At a SACGHS meeting last week, FORCE said that Myriad Genetics sales representatives discourage doctors from referring patients to genetic counselors, and recommended the committee make recommendations for greater monitoring of such actions. SACGHS plans to invite Myriad to respond to the allegations.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.